|
BiPAPgroup(19) |
Standardtherapy (11) |
Control group (15) |
Anthropometric characteristics |
|
|
|
Age,years |
55.4 ± 10.3 |
53.15 ± 7.68 |
49.75 ± 6.78
p-0.623 |
Men:Women |
18/1 |
11/0 |
12/3 |
Weight, kg |
|
|
144.3 ± 32.26
p-0.421 |
BMI, kg/m2 |
41.05 ± 5.95 |
39.06 ± 6.92 |
38.06 ± 7.57
p-0.485 |
Waist circumference, cm |
134.6 ± 13.32 |
130.3 ± 16.29 |
132.16 ± 19.76
p-0.421 |
Smokers (current:former:nonsmoker) |
12:6:1 |
5:4:2 |
7:2:1 |
Sleep study characteristics |
|
|
|
Mild-moderateOSA (AHI <30e/h) |
3/19 (16%) |
2/11(18%) |
0 |
Severe OSA (AHI >30e/h) |
16/19(84%) |
9/11(82%) |
15/15(100%) |
AHI, events/hour |
50.93 ± 25.4 |
49.14 ± 28.3 |
65.94 ± 30.58
p-0.321 |
Sleep duration, min |
211 ± 21.6 |
209 ± 45.9 |
203.5 ± 44.3
p-0.087 |
Time SpO2 <90%, % |
79.43 ± 28.9 |
56.35 ± 37.8 |
50.43 ± 23.41
p-0.114 |
Lipid profiles |
|
|
|
HDL, mmol/l |
1.20 ± 0.29 |
1.35 ± 0.38 |
1.31 ± 0.41
p-0.912 |
LDL, mmol/l |
2.74 ± 0.75 |
3.38 ± 1.06 |
3.25 ± 1.05
p-0.428 |
VLDL, mmol/l |
0.94 ± 0.53 |
0.83 ± 0.34 |
0.81 ± 0.25
p-0.781 |
Tot Chol, mmol/l |
4.86 ± 1.03 |
5.57 ± 0.99 |
5.39 ± 1.28
p-0.613 |
Triglycerids, mmol/l |
1.81 ± 0.64 |
1.83 ± 0.76 |
1.83 ± 0.56
p-0.345 |
Glucometabolic markers |
|
|
|
Fasting glucose,mmol/l |
6.24 ± 2.71 |
4.87 ± 7.66 |
6.01 ± 2.1 |
Immunoreactive insulin, mUI/ml |
18.47 ± 10.65
p*-0.316 |
15.3 ± 8.67
p**-0.229 |
19.46 ± 14.26
p***-0.151 |
HOMA index |
4.18 ± 2.37 |
3.43 ± 2.48 |
6.01 ± 7.21
p***-0.177 |
HbA1C, % |
6.59 ± 1.31
p*-0.253 |
5.92 ± 0.63
p**-0.103 |
6.04 ± 0.82
p***-0.210 |
Biomarkers |
|
|
|
Isoprostanespg/µml crn |
0.164 ± 0.09 |
0.125 ± 0.05
p**-0.172 |
0.049 ± 0.02
p***-0.000 |
NT –pro-BNP pmol/ml |
51.75 ± 46.3 |
39.12 ± 8.76
p**-0.453 |
- |
Resistin,ng/ml |
8.53 ± 7.96 |
4.45 ± 0.78
p**-0.375 |
2.51 ± 0.75
p***-0.078 |
FFA,mmol/l |
0.189 ± 0.06 |
0.258 ± 0.11
p**-0.273 |
0.198 ± 0.10
p***-0.305 |
p*- Mann -Whithney comparison BiPAP vs standard; p**- Mann -
Whithney comparison standard vs controls ; p***- Mann -Whithney
comparison BiPAP vs controls. |